In the normal mammary gland, the basal epithelium is known to be bipotent and can generate either basal or luminal cells, whereas the luminal epithelium has not been demonstrated to contribute to the basal compartment in an intact and normally developed mammary gland. It is not clear whether cellular heterogeneity within a breast tumor results from transformation of bipotent basal cells or from transformation and subsequent basal conversion of the more differentiated luminal cells. Here we used a retroviral vector to express an oncogene specifically in a small number of the mammary luminal epithelial cells and tested their potential to produce basal cells during tumorigenesis. This in-vivo lineage-tracing work demonstrates that luminal cells are capable of producing basal cells on activation of either polyoma middle T antigen or ErbB2 signaling. These findings reveal the plasticity of the luminal compartment during tumorigenesis and provide an explanation for cellular heterogeneity within a cancer.
INTRODUCTION
Human breast tumors take many years to form and are usually clonal. 1, 2 The majority of human breast cancers are comprised primarily of cells resembling the luminal layer of the normal mammary epithelium and are thought to originate in these cells. However, some human breast tumors also harbor both luminaland basal-like cells, or have a basal-like expression profile. 3, 4 Therefore, heterogeneous tumors must be derived from basal cells that become luminal cells, or vice versa.
In early mammary development, both the luminal and basal epithelial compartments are generated from bipotent progenitors expressing markers of both lineages. 5, 6 After birth, although it is controversial whether basal cells can give rise to luminal cells in an unperturbed mammary gland, they retain the capability of regenerating a complete ductal tree after isolation and transplantation into an epithelia-cleared fat pad. 6, 7 However, luminal cells have been repeatedly demonstrated to be lineage-restricted and incapable of generating basal cells in either the intact mammary gland or upon transplantation. [5] [6] [7] [8] [9] It is unclear whether this differentiated state in luminal cells precludes the development of basal cells during tumorigenesis.
There have not been any studies that fully address this question. Previous studies in transgenic rodent models utilized congenitally expressed oncogenes, often having an impact on mammary gland development, and further lacked highly lineagedefined promoters. [10] [11] [12] [13] Other studies relied on ex-vivo lineage enrichment and alteration, followed by transplantation. [14] [15] [16] [17] Clinical BRCA1 patients have an expanded luminal progenitor population and develop basal-like tumors, and this correlation was interpreted to suggest a luminal cell origin for these tumors. 18 However, later studies indicate that the luminal compartment in these patients show a basal-like profile and may not have properly differentiated in the first place. 19 Therefore, it is unclear whether committed luminal cells in a fully developed and intact mammary gland-upon the gain of oncogenic mutations-can generate basal cells in their evolution to breast cancer. Here we sought a direct answer to this question using a retroviral vector to selectively infect a small number of mammary luminal cells in vivo and to trace clonal tumor initiation events, according the emerging standard for tumor cell-of-origin studies. [20] [21] [22] [23] [24] Resolving this issue will help explain the source of cellular heterogeneity in human breast cancer, which contributes to therapy resistance.
RESULTS AND DISCUSSION
RCAS viral integration is restricted to the luminal compartment in WAP-tva mice Here, we tested whether committed luminal cells can give rise to basal cells during tumorigenesis. Whey acidic protein (WAP) is produced selectively by committed luminal cells within mammary ducts and alveoli. 26, 27 We recently generated a transgenic FVB mouse line using the luminal WAP promoter to drive the expression of cDNA encoding the TVA receptor, 28 which is both necessary and sufficient for infection by avian leukosis virusderived vector RCAS. 25 We utilize this system here to introduce two oncogenes (polyoma middle T antigen (PyMT) or ErbB2) into committed luminal mammary epithelial cells in a fully developed mammary gland and evaluated the lineage potential during tumorigenesis.
To reconfirm that RCAS integration is restricted to the WAP+ luminal cell population, RCAS-βactin-HA 29 was injected intraductally into eight adult WAP-tva mice (14-18 weeks of age; 1 × 10 7 IU per gland; one set of 2-4 glands per mouse). Uninjected glands were retained for each mouse as an internal control in this and all subsequent experiments, as opposed to treatment randomization. Figures S1B and C) . Our previous study of the infection rate using this virus detected~3000 infected cells per gland. 28 Thus, the total number of HA+ basal cells are estimated to be three per mammary gland in this current study. These data demonstrate that in the WAP-tva mouse line, viral integrationand therefore oncogene expression-is highly selective for the luminal epithelium. Next, we evaluated the lineage plasticity of the HA-tagged cells in an unperturbed mammary gland. The RCAS-βactin-HA-infected mammary glands of eight WAP-tva mice each were collected 2 and 6 weeks post infection for co-immunofluorescence for the above markers. Again, 99% of the HA+ cells co-stained for K8 at both time points, but none co-localized with K5 and only one cell Figure S1 . The WAP-tva transgenic mouse line has been previously described. 28 All mice were bred and maintained in accordance with the animal protocol and guidelines approved by the BCM Institutional Animal Care and Use Committee. RCAS viral culture and mammary intraductal injection has been previously described. 44 For immunofluorescence staining, antibodies used are as follows: mouse anti-HA (1:500; Covance, Princeton, NJ, USA, MMS-101P), rabbit anti-K5 (1:200; Covance, PRB-160P), rabbit anti-p63 (1:200; Biolegend, San Diego, CA, USA, 619002) and rat anti-K8 (1:200; University of Iowa Hybridoma Bank, Iowa City, IA, USA, Troma-I). Cells were quantified using the WCIF ImageJ package (www.uhnresearch.ca/ wcif). Thresholds for each channel were individually determined by evaluation against control ducts. HA+ cells were manually selected and quantified using the Nucleus Counter plugin on the DAPI+ channel. Protein co-localization was ascertained using the Colocalization Highlighter plugin. Co-localized protein was required to encircle a nucleus to be considered a positive cell. For nuclear stains, cellular co-localization was manually quantified using thresholded images in cells containing both the nuclear marker and encircled by the cytoplasmic marker.
with p63 at 2 weeks, whereas only 5 cells co-stained with either K5 or p63 at 6 weeks (Figures 1d-i, k and l, and Supplementary Figures S1D-I). These data indicate that the infected luminally cells remained luminally restricted even after extended periods of time (equivalent to~14 estrus cycles at the 6-week time point), confirming previous reports that in postnatal mammary glands luminal cells contribute only to the luminal compartment. 6, 7 PyMT-initiated tumorigenesis from luminal cells leads to the formation of early lesions and tumors that both harbor basal cells To test whether oncogenic stress could cause committed luminal cells to generate basal cells, eight adult WAP-tva mice (12-14 weeks of age) were intraductally injected with RCAS virus expressing the gene encoding HA-tagged PyMT (RCAS-PyMT-HA). 30 PyMT is a potent oncoprotein widely used as a model for breast cancer development that activates Src and phosphatidylinositol-3-kinase. 31, 32 It can rapidly induce mammary tumors in mice either transgenic for PyMT 33 or infected with RCAS-PyMT-HA, 25 and the resultant tumors most closely resemble the clinical LumB subtype. 34, 35 In our model, we find that the lesions and tumors generated have a solid-cribiform and cribiform-micropapillary pathology, respectively (Supplementary Figure S2A, B and F) . Early precancerous lesions can be detected by 7 days following RCASPyMT-HA injection; 25 thus, at this point, three mice were euthanized and their mammary glands were stained by co-immunofluorescence for the HA tag and either K8 or K5. In the 30 lesions evaluated, the majority of HA+ cells produced K8, as expected (median = 67.3%; Figure S3) . As only a few basal cells existed among this infected population, the overwhelming majority of lesions-and the basal cells within them-must have arisen from committed luminal cells.
Tumors that developed in the remaining five mice were collected for co-immunofluorescence analysis for the HA tag in PyMT and either a luminal or a basal marker. As expected, the majority of tumor cells were positive for K8 (median = 79.8%; Figures 2e and h, and Supplementary Figure S4C ) and they appeared to be well differentiated with a low nuclear grade (Supplementary Figure S2B) . However, again a small subset of HA+ tumor cells stained for K5 (median = 1.17%; Figures 2f and I, and Supplementary Figure S4D) . These K5+ cells were predominantly, although not exclusively, localized in close proximity to the infiltrating stroma and were well organized similar to a basal epithelium. This finding was confirmed by staining for p63 (median = 2.49%, Figures 2g and j, and Supplementary Figure S4E) . Together, these data suggest that PyMT expression in luminal cells leads to the formation of early lesions and tumors that both harbor a small subset of welldifferentiated and -organized basal cells.
ErbB2-initiated tumorigenesis from luminal cells also leads to the formation of early lesions and tumors that harbor basal cells Next, we tested whether a cellular oncogene commonly altered in human breast cancer can also cause committed luminal cells to produce basal cells. ErbB2 encodes a member of the epidermal growth factor receptor family of tyrosine kinases and is amplified and overexpressed in~25% of human breast cancers. 36, 37 Although ErbB2 tumors cluster together and are considered their own subtype, the category can be further divided into those tumors that are more luminal-like and those that are more basallike. 3, 38 In our system, we find that the ErbB2 precancerous lesions have a solid or solid-cribirorm pathology, but mature tumors often develop squamous metaplastic pockets (Supplementary Figures . Cellular co-localization was quantified as described in Figure 1 . Quantifications represent percentage (mean ± s.e.m.) of K5+/K8+ double-positive cells and K5 − /K8 − double-negative cells over total HA+ cells for 10 precancerous lesions from each of 3 mice, and 5 (PyMT) and 7 (ErbB2) mature tumors, to ensure detection of cellular conversion occurred in multiple mice at each stage. P-value is calculated using a non-parametric Kruskal-Wallis test, to account for large variability in the data.
S2C-F), making this oncogene a suitable candidate for the study of tumor heterogeneity. Ten adult (13-16 weeks of age) WAP-tva mice were injected intraductally with RCAS-ErbB2-HA, which carries a constitutively activated ErbB2. 25 RCAS-ErbB2-HA leads to early precancerous lesions in 2 weeks 29, 39 and therefore three mice at this time point were euthanized and their infected mammary glands were co-stained for HA and either K8 or K5. Most of the resulting early lesions maintained a high percentage of luminal K8+ cells, as expected, although some downregulated or lost K8 (median = 81.8%; Figures 3a and c, and Supplementary Figure S5A) . As in the PyMT-induced early lesions, some of these early lesions also gained a small subset of K5+ cells (median = 0.21%; Figures 3b and d, Supplementary Figure S5B) , which existed mainly as isolated single events.
Tumors arising in the remaining seven infected mice appeared heterogeneous, as we reported previously. 40 The majority of the tumor mass was glandular and comprised of dense luminal K8+ cells that were accompanied by few K5+ basal-like cells (Figures 3e and f, and Supplementary Figures S5C and D) . In contrast, large pockets of K5+ squamous metaplastic cells developed in four of the seven tumors ( Figure 3J Figures S5E-H) . Squamous metaplasia represents a rare subtype of basal breast cancers with poor prognosis. 41, 42 The observations in this study suggest that squamous metaplastic cells within breast cancer may have an origin in the luminal epithelium.
Flow cytometry analysis of cellular lineages
We next wanted to evaluate the lineage profiles by flow cytometry for both PyMT and ErbB2 lesion-bearing mammary glands. Normal uninfected control mammary gland cells clearly showed both luminal (CD24 high CD49f+) and basal (CD24 low CD49f+) lineages, as reported. 8 For both the PyMT and ErbB2 lesions, although the majority of the HA+ cells remained within the luminal gate, a significant subset was detected within the basal gate and a substantial proportion of cells massed between the basal and luminal gates (Figure 4a and b, and Supplementary Figure S6 ). This observation confirmed basal conversion of luminal cells during tumorigenesis and further suggests that even cells that appear in a luminal or basal state by standard immunofluorescence methods may actually be in a transitioning state detectable via flow cytometry. Previous studies have also shown that tumorigenesis can induce the formation of a new cytometric profile, which is enriched for tumor stem cells. 12 Future studies may elucidate the role for these transitioning cells.
Taken together, both PyMT and ErbB2 can stimulate significant luminal-to-basal transition. Therefore, oncogenic stress can cause committed luminal cells to form additional cell lineages, including basal cells and squamous metaplastic cells as well, unveiling oncogene-driven plasticity of committed luminal cells during carcinogenesis. These findings provide further support for the idea that luminal cells can be the cells of origin of heterogeneous breast cancers, including those that are basal-like, and suggest that intratumoral heterogeneity does not need to arise from transformation of bipotential progenitor cells.
K8/K5 double-positive cells exist in both early lesions and frank tumors The detection of both a large population of K5+ cells and a large population of K8+ cells in some caErB2-induced tumors suggests that some of the tumor cells may be double positive for both basal and luminal markers. Therefore, tri-immunofluorescence staining for K8/K5/HA was used to identify double lineage cells among the provirus+ population (based on HA staining). In PyMT-induced early lesions and tumors, K8+K5+ cells were detected in 2.26 ± 1.0% and 2.17 ± 0.7% of the provirus+ cells, respectively (Figures 4c-e) . In ErbB2-induced early lesions and tumors, K8+K5+ cells were found in 0.84 ± 0.3% and 5.11 ± 1.8% of provirus+ cells, respectively (Figures 4f-i; P o0.03 ). These data demonstrate that K8/K5 double-positive cells exist in both early lesions and frank tumors induced by both PyMT and ErbB2. These double-positive cells may represent a transitional state between the luminal and basal compartments. Alternately, cells positive for both lineage markers may have stem cell properties or be cancer stem cells. 6, 43 We further quantified the numbers of double-negative cells, as these may represent an alternate and possibly more dedifferentiated transition state. Here we found that PyMT lesions and tumor had 0.54 ± 0.1% and 0.51 ± 0.2% K5/K8 double-negative cells among provirus+ cells. ErbB2 lesions and tumors had 0.94 ± 0.4% and 1.68 ± 0.5% double-negative cells among provirus+ cells (Figures 4e and i) .
Neither the lineage double-positive nor the double-negative cell population size significantly increased with the progression from precancerous lesions to tumors in the PyMT model; however, there was a significant increase in the numbers of double-positive cells in the ErbB2 model. These cells may represent a transitioning or possibly stem-like cellular state, suggested by previous literature. 12 However, this emergent cellular population would necessitate further study to fully elucidate the function.
CONCLUSION
Using retrovirus-mediated in-vivo lineage tracing, we show that oncogenic signaling can cause committed luminal cells to form additional cellular lineages, exposing the plasticity of formerly committed and lineage-restricted mammary luminal epithelial cells. This observation suggests that intratumoral heterogeneity does not need to arise from transformation of a cell with multipotent potential. Rather, heterogeneity may be a natural consequence of oncogene activation regardless of the cell of origin. Consequently, breast cancer prevention should not solely focus on targeting a specific multipotent cell population. Understanding the molecular mechanism of luminal cell plasticity under oncogenic stress may lead to new molecular targets for preventing basal-like and metaplastic breast cancer.
